BridgeBio Pharma, Inc. — Director's Dealing 2020

Jun 3, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2020-06-01

Reporting Person: Sinha Uma (Chief Scientific Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-06-01	Restricted Stock Units	$	A	7500	Acquired		Common Stock (7500)	Direct

Footnotes

F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

F2: The RSUs will vest approximately four years with a vesting commencement date of May 16, 2020. 6.25% of the RSUs will vest on August 16, 2020 and an additional 6.25% will vest in quarterly installments thereafter, subject to continued service with the Issuer or any of its subsidiaries through each applicable vesting date.